Epidermolysis Bullosa Market Size, Trends, Industry Analysis, Overview, Share And Forecast 2023 To 2030

Market Overview:

Epidermolysis bullosa (EB) is a group of rare genetic conditions that cause easy blistering of the skin and mucous membranes. The condition ranges from very mild to severe. In severe forms, even minor friction or trauma causes large blisters or skin loss. The major treatment modalities available include wound care, pain management, surgery, and autologous cell therapy. 

The global Epidermolysis Bullosa Market is estimated to be valued at US$ 3,429.30 Mn in 2023 and is expected to exhibit a CAGR of 11. % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. 

Market key trends:

One of the major trends in the EB market is increasing R&D for autologous cell therapy. Autologous cell therapy involves transplantation of the patient's own genetically corrected cells to restore the function of defective genes. Researchers are evaluating autologous cell therapies such as gene-corrected fibroblast transplantation and induced pluripotent stem cell transplantation to provide permanent cure for EB. Companies such as Amryt Pharma and Abeona Therapeutics are developing gene therapy and autologous stem cell transplantation treatments offering encouraging results in clinical trials. Other ongoing research includes development of biological skin equivalents and topical products to treat wounds and protect skin barrier function in EB patients.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/epidermolysis-bullosa-therapeutics-market-2214

Segment Analysis 

The global epidermolysis bullosa market is segregated into junctional EB, dominant dystrophic EB, and recessive dystrophic EB, based on disease type. The dominant dystrophic EB segment dominated the market in 2022 and is estimated to witness high growth over the forecast period. Dominant dystrophic EB is the most common form of EB and is characterized by mechanically fragile skin and mucous membranes. Easy blistering and shearing of the skin layers are common symptoms of dominant dystrophic EB. 

Key Takeaways

The global epidermolysis bullosa market size was valued at US$ 3,429.30 Mn in 2023 and is expected to reach US$ 7,385.97 Mn by 2030, growing at a CAGR of 11% over the forecast period.

Regional Analysis

North America dominated the global market in 2022 and is estimated to maintain its dominance over the forecast period, growing at a CAGR of 11.3%. This is attributed to the increasing prevalence of EB, rising research funding for developing therapies, and presence of key pharmaceutical companies in the region. 

Key Players Analysis 

Key players operating in the epidermolysis bullosa market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair. Amryt Pharma's Oleogel-S10 is the only FDA approved topical treatment for EB. Krystal Biotech is developing an innovative gene therapy for dystrophic EB.